If you have invested in TRUEinvivo® already (and over 70 of you have) then, as ever, we thank you for your confidence and support for the company and the team. You already know that we send out an investor update briefing every 2-3 months and that we organise investor get-togethers once a year. You also know that we welcome questions and interest from our investors at any time.
If you are a potential investor then thank you too for your interest in TRUEinvivo®.
You will have read about the company’s technical progress (not least on these web pages) but there is much more we can tell you about the market, our IP, the business plan and the hospitals and radiotherapy centres (in the UK and overseas) that have approached us to be part of our research and development programme.
We raised our first seed round early in 2018 which enabled us to build prototypes in-house. We launched our second seed round in late 2018 and that enabled us to get pre-production readers built by our design and development partner, Morgan Innovation and Technology. At the end of 2019 we launched our third round in order to complete regulatory approval and commercialise our products. Just to be clear, this page is not a formal invitation to invest in the company. It is for general information only.
If you would like more information about TRUEinvivo please contact our CFO Chris Budleigh (email@example.com) or our CEO Nigel Biggs (firstname.lastname@example.org).
We have a real team ethos at TRUEinvivo® and we strive to make our investors part of that team – just as much or as little as you want to be! We look forward to talking to or meeting you.